Huafu Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 28 yuan. The main reasons for the rating include: 1) achieving positive growth under the high Q1 performance base, with strong oral liquid performance; 2) strengthening academic leadership and continuing enrichment of the Chinese medicine innovation pipeline; 3) equity incentive guidelines reflect the company's development confidence; 4) The equity incentive target is: based on 2023 revenue, with a revenue growth rate of not less than 18% in 2024, or based on 2023 net profit, the net profit growth rate in 2024 will not be less than 20%; based on 2023 non-injectable product revenue, the revenue growth rate for non-injectable products will not be less than 20% less than 22%. (Mainichi Keizai Shimbun)
华福证券4月14日发布研报称，给予康缘药业（600557.SH）买入评级，目标价格为28元。评级理由主要包括：1）Q1业绩高基数下实现正增长，口服液表现强劲；2）加强学术引领，中药创新管线持续丰富；3）股权激励指引全年目标，体现公司发展信心；4）司股权激励目标为：以2023年营收为基数，2024年营收增长率不低于18%，或以2023年净利润为基数，2024年净利润增长率不低于20%；以2023年非注射剂产品营收为基数，2024年非注射剂产品营收增长率不低于22%。（每日经济新闻）
Huafu Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 28 yuan. The main reasons for the rating include: 1) achieving positive growth under the high Q1
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.